Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.
about
Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
P2860
Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Monitoring drug and antidrug l ...... n a stable biologic treatment.
@en
type
label
Monitoring drug and antidrug l ...... n a stable biologic treatment.
@en
prefLabel
Monitoring drug and antidrug l ...... n a stable biologic treatment.
@en
P2093
P2860
P356
P1476
Monitoring drug and antidrug l ...... n a stable biologic treatment.
@en
P2093
Alexandra Peltea
Andra Balanescu
Andreea Borangiu
Cecilia Gainaru
Cosmin Constantinescu
Daniela Opriş
Denisa Predeteanu
Diana Mazilu
Giorgiana Luca
Ioana Saulescu
P2860
P304
P356
10.1155/2014/702701
P407
P50
P577
2014-05-20T00:00:00Z